Amphipathic dextran-doxorubicin prodrug micelles for solid tumor therapy
Amphipathic dextran-doxorubicin prodrug micelles for solid tumor therapy
复制标题
用于实体瘤治疗的两亲性右旋糖酐-阿霉素前药胶束
DOI：
10.1016/j.colsurfb.2017.06.023
复制
发表时间：
2017-10-01
影响因子：
5.8
通讯作者：
Cao, Aoneng
中科院分区：
文献类型：
--
作者：
Jin, Rong;Guo, Xuelian;Cao, Aoneng
A group of micelles self-assembled from deoxycholic acid-doxorubicin-conjugated dextran (denoted as Dex-DCA-DOX) prodrugs were designed and prepared for pH-triggered drug release and cancer chemotherapy. These prodrugs could be successfully produced by chemically coupling hydrophobic deoxycholic acid (DCA) to dextran hydrazine (denoted as Dex-NHNH2) and hydrazone linker formation between doxorubicin (DOX) and Dex-NHNH2. These Dex-DCA-DOX prodrugs self-assembled to form micelles under physiological conditions with varied particle sizes depending on molecular weight of dextran, degree of substitution (DS) of DCA and DOX. After optimization, Dex10k-DCA9-DOX5.5 conjugate comprising dextran of 10 kDa, DCA of DS 9 and DOX loading content of 5.5 wt%, formed the micelles with the smallest size (110 nm). These prodrug micelles could slowly liberate DOX under physiological conditions but efficiently released the drug at an acidified endosomal pH by the hydrolysis of acid-labile hydrazone linker. In vitro cytotoxicity experiment indicated that Dex10k-DCA9-DOX5.5 micelles exerted marked antitumor activity against MCF-7 and SKOV-3 cancer cells. Besides, intravenous administration of the micelles afforded growth inhibition of SKOV-3 tumor bearing in nude mice at a dosage of 2.5 mg per kg with anti-cancer efficacy comparable to free DOX-chemotherapy but low systemic toxicity. This study highlights the feasibility of bio-safe and efficient dextran-based prodrug micelles designed for cancer chemotherapy. (C) 2017 Elsevier B.V. All rights reserved.
